Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAAS Blockade With Valsartan in Kidney Transplant Recipients With Urinary Renal Progenitor Cells
2018-003936-62Phase 4Active
- Sponsor
- Bellvitge Institute for Biomedical Research
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of valsartan in transplant glomerulopathy (TG) and Kidney allograft dysfunction (2 arms), sponsored by Bellvitge Institute for Biomedical Research. Primary endpoint: Glomerular filtration rate at 24 months. Started Apr 2019; status: active.
02
Drugs
valsartan
03
Conditions
transplant glomerulopathy (TG)Kidney allograft dysfunction
Beyond the preview
Go deeper on 2018-003936-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003936-62.